EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Oral Anticoagulation After Atrial Fibrillation Ablation: An Updated Systematic Review and Meta‐Analysis of 267 443 Patients

Andrea Matteucci iD, Marco Valerio Mariani iD, Claudio Pandozi, Michela Bonanni, Marco Frazzetto iD, Nicola Pierucci, Vincenzo Mirco La Fazia iD, Raffaele Maria Bruti, Marta Palombi iD, Antonio Vernile, Carlo Lavalle, Carmine Dario Vizza und 3 weitere

European Journal of Haematology · 2026-06 · 116 (6) · 915-927

DOI: 10.1111/ejh.70155 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Haematology, online erschienen am 05.03.2026. Verfasst von Andrea Matteucci und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Catheter Ablation. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether long‐term oral anticoagulation (OAC) is necessary after apparently successful atrial fibrillation (AF) ablation remains uncertain. Guidelines recommend continuation based on CHA 2 DS 2 ‐VASc score rather than procedural success, yet contemporary evidence, including randomized trials, has produced conflicting results. We aimed to provide an updated and comprehensive assessment of OAC discontinuation following AF ablation.

Methods

We conducted a systematic review and meta‐analysis in patients who discontinued versus continued OAC after AF ablation. Outcomes included thromboembolic events (TE) and major bleeding events (MBE). Random‐effects models with Hartung–Knapp correction were applied. Heterogeneity, publication bias, influence analyses, subgroup analyses, and risk‐of‐bias domains were assessed.

Results

In 28 studies (267 443 patients), OAC discontinuation significantly reduced the composite of TE and MBE (RR 0.44, 95% CI 0.32–0.61), driven by a marked decrease in bleeding (RR 0.25, 95% CI 0.16–0.39), without excess thromboembolic risk (RR 0.84, 95% CI 0.64–1.12). Findings remained consistent across subgroup analyses (study design, CHA 2 DS 2 ‐VASc, geographic region), with sensitivity and meta‐regression confirming robustness and no significant effect modifiers. Funnel plots showed no significant asymmetry for TE, whereas MBE demonstrated evidence of small‐study effects.

Conclusions

Discontinuation of OAC after successful AF ablation markedly reduces MBE without a statistically significant increase in TE, highlighting the need for individualized post‐ablation anticoagulation strategies. Randomized trials are needed to confirm the safety of tailored oral anticoagulant discontinuation in selected patients, supported by careful long‐term follow‐up and shared decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsCatheter AblationHumansAdministration, OralTreatment OutcomeThromboembolismHemorrhage

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Clinical and Rehabilitation Cardiology Division, San Filippo Neri Hospital, Rome, Italy.
  • Department of Experimental Medicine, Tor Vergata University, Rome, Italy.
  • Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, "Sapienza" University of Rome, Rome, Italy.
  • Cardiocentro Ticino, Department of Cardiology, Lugano, Switzerland.
  • Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA.
  • Department of Interventional Cardiology, UOC Cardiologia, Sandro Pertini Hospital, Rome, Italy.

ORCID-Profile: Andrea Matteucci, Marco Valerio Mariani, Marco Frazzetto, Vincenzo Mirco La Fazia, Marta Palombi

Zitieren

APA

Matteucci, A., Mariani, M. V., Pandozi, C., Bonanni, M., Frazzetto, M., Pierucci, N., La Fazia, V. M., Bruti, R. M., Palombi, M., Vernile, A., Lavalle, C., Vizza, C. D., Fedele, S., Nardi, F., & Colivicchi, F. (2026). Oral Anticoagulation After Atrial Fibrillation Ablation: An Updated Systematic Review and Meta‐Analysis of 267 443 Patients. European Journal of Haematology, 116(6), 915-927. https://doi.org/10.1111/ejh.70155

Vancouver

Matteucci A, Mariani MV, Pandozi C, Bonanni M, Frazzetto M, Pierucci N, et al. Oral Anticoagulation After Atrial Fibrillation Ablation: An Updated Systematic Review and Meta‐Analysis of 267 443 Patients. European Journal of Haematology. 2026;116(6):915-927. doi:10.1111/ejh.70155

BibTeX
@article{Matteucci2026,
  author = {Matteucci, Andrea and Mariani, Marco Valerio and Pandozi, Claudio and Bonanni, Michela and Frazzetto, Marco and Pierucci, Nicola and La Fazia, Vincenzo Mirco and Bruti, Raffaele Maria and Palombi, Marta and Vernile, Antonio and Lavalle, Carlo and Vizza, Carmine Dario and Fedele, Silvio and Nardi, Federico and Colivicchi, Furio},
  title = {Oral Anticoagulation After Atrial Fibrillation Ablation: An Updated Systematic Review and Meta‐Analysis of 267 443 Patients},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {116},
  number = {6},
  pages = {915--927},
  doi = {10.1111/ejh.70155}
}
Kostenlos starten →